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Background: Dysregulation of glycoproteins is closely related with many diseases. Quantitative proteomics methods are
powerful tools for the detection of glycoprotein alterations. However, in almost all quantitative glycoproteomics studies,
trypsin is used as the only protease to digest proteins. This conventional method is unable to quantify N-glycosites in very
short or long tryptic peptides and so comprehensive glycoproteomics analysis cannot be achieved.
Methods: In this study, a comprehensive analysis of the difference of N-glycoproteome between hepatocellular
carcinoma (HCC) and normal human liver tissues was performed by an integrated workflow combining the
multiple protease digestion and solid phase based labeling. The quantified N-glycoproteins were analyzed by
GoMiner to obtain a comparative view of cellular component, biological process and molecular function.
Results/conclusions: An integrated workflow was developed which enabled the processes of glycoprotein coupling,
protease digestion and stable isotope labeling to be performed in one reaction vessel. This workflow was firstly
evaluated by analyzing two aliquots of the same protein extract from normal human liver tissue. It was demonstrated
that the multiple protease digestion improved the glycoproteome coverage and the quantification accuracy. This
workflow was further applied to the differential analysis of N-glycoproteome of normal human liver tissue and that with
hepatocellular carcinoma. A total of 2,329 N-glycosites on 1,052 N-glycoproteins were quantified. Among them, 858
N-glycosites were quantified from more than one digestion strategy with over 99% confidence and 1,104 N-glycosites
were quantified from only one digestion strategy with over 95% confidence. By comparing the GoMiner results of the
N-glycoproteins with and without significant changes, the percentage of membrane and secreted proteins and their
featured biological processes were found to be significant different revealing that protein glycosylation may play the
vital role in the development of HCC.
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Protein glycosylation, one of the most important post-
translational modifications of proteins, plays a pivotal role
in many biological pathways including cell-cell signaling,
ion transport, protein stability, vesicle trafficking and so
on [1,2]. Aberrant glycosylation has been proved to be
associated with disease progression, carcinogenesis and
immunity [3-5]. Currently, many glycosylated proteins
are approved to be clinical biomarkers, e.g., prostate-
specific antigen (PSA) in prostate cancer, cancer anti-
gen (CA) 125 in ovarian cancer, α-fetoprotein (AFP) in
HCC, and HER2/neu in breast cancer. Therefore, quanti-
tative analysis of disease-associated alteration in protein
glycosylation can help in prognosis, diagnosis and sur-
veillance after surgery.
Several methods have been developed for glycoproteo-
mics analysis, e.g. hydrazide chemistry [6], hydrophilic
interaction chromatography (HILIC) [7], lectin affinity
chromatography [8], boronic acid chromatography [9],
titanium dioxide [10], etc. Considering the facts that hy-
drazide chemistry can isolate N-glycopeptides with speci-
ficity of more than 90% [11] and is compatible with stable
isotope labeling, we previously developed a solid phase
based labeling approach by integration of N-glycopeptide
enrichment and the fast and simple dimethyl labeling de-
rivatization on hydrazide resins for relative quantification
of protein glycosylation. It was found that this approach
has higher enrichment recovery and detection sensitivity
than the dimethyl labeling approach conventionally per-
formed in solution [12].
Liver is the largest visceral organ which is necessary
for survival in human body. It involves in a wide range
of biological processes, including detoxification, protein
synthesis, and production of biochemical necessary for
digestion. Liver cancer is the third most common cause
of cancer death after lung cancer and stomach cancer
[13,14]. Newly developed proteomic techniques have
been applied to deeply analyze the proteins and their
modifications in human liver tissue. Song et al. conducted
a large-scale phosphorylation analysis of human liver and
experimentally identified 9,719 p-sites in 2,998 proteins
[15]. Chen et al. identified 939 N-glycosylation sites in
523 N-glycosylated proteins by combining multiple prote-
ase digestion and hydrazide chemistry for human liver
N-glycoproteome analysis [16]. Furthermore, several stud-
ies on comparative analyses of HCC and normal human
liver tissues were carried out to screen potential disease-
specific biomarkers. In our lab, Wang et al. have done
quantitative analysis of HCC and normal human liver
tissues in ~30 h by using a fully automated system which
quantified ~1,000 proteins [17]. Moreover, the difference
in the phosphoproteomes of HCC and normal human
liver tissues was also investigated by Song et al. [18], with
over 1,800 phosphopeptides corresponding to ~1,000phosphoproteins reliably quantified in only 42 h using a
pseudo triplex labeling system. Nevertheless, the differ-
ences in the N-glycoproteome of HCC and normal human
liver tissues was still of great importance to be extensively
studied.
Using multiple proteases with complementary cleavage
specificities for digestion can efficiently improve protein
identifications and proteome sequence coverage. This method
has already been applied to qualitative analysis of proteome,
phosphoproteome, and glycoproteome [16,19-22]. How-
ever, no attempt was performed to quantitative analysis
of proteome, phosphoproteome and glycoproteome. In
this study, digestion with three different digestion strat-
egies (trypsin, trypsin & Glu-C, and chymotrypsin) was
combined with the solid phase based labeling approach
to comparatively analyze the differential expression of
N-glycoproteome between HCC and normal human
liver tissues. A total of 2,329 N-glycosites matched with
the motif N-X-S/T (X can be any amino acid except pro-
line) on 1,052 N-glycoproteins were quantified by this
strategy, which is the largest dataset of quantitative in-
formation between human HCC and normal liver tis-
sues up to now.
Results
An integrated workflow incorporated with multiple
protease digestion and solid phase based labeling
For a convenient and fast-processing workflow, all the
processes including glycoprotein coupling, protease diges-
tion and stable isotope labeling should be performed in
one reaction vessel. As shown in Figure 1, the workflow
developed in this study enabled the performing of all the
above steps in one vessel. The extract of human liver tis-
sues was oxidized by sodium periodate in a centrifugal
tube, followed by adding hydrazide resins to the tube for
the capturing of the oxidized glycoproteins. After washing,
the resins with captured glycoproteins were still left in the
tube. Protease was then added to the tube for the diges-
tion of the captured glycoproteins on the hydrazide resins.
After digestion, the non-glycosylated peptides were re-
leased from the resins and washed away. The remaining
glycopeptides on the resins were left in the tube. Dimethyl
labeling reagents were then added to the tube for stable
isotope labeling of the glycopeptides on the resins. Finally,
these labeled N-glycopeptides were released by deglycosyl-
ation with PNGase F. After centrifugation, the released
light and heavy labeled deglycosylated peptides were
collected and then pooled together for nanoLC-MS/MS
analysis.
This workflow firstly benefits from the fact that the en-
richment process was carried out on the protein level. As
the glycoproteins are covalently captured on the hydrazide
resins, the exchanges of buffers are extremely convenient.
Since most of the membrane proteins are glycosylated,
Figure 1 The integrated workflow for high-throughput quantitative analysis of N-glycoproteome of human liver tissues. Three digestion
strategies by using proteases with different cleavage specificities were applied to digest the captured N-glycoproteins.
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added in the homogenization buffer to facilitate the ex-
tract of membrane glycoproteins. It is challenging to re-
move these detergents in conventional approach, while in
this workflow they are easily removed by washing the hy-
drazide resins with 80% ACN. This solid phase design also
benefits the downstream sample processes. For example,
it allows the labeling of glycopeptides on the hydrazide
resins, i.e. solid phase based labeling of glycopeptides for
quantitative glycoproteomics. This labeling method was
previously proved to be accurate and has good enrichment
recovery and high detection sensitivity [12].
Using multiple proteases for digestion is an essential
approach to increase the sequence coverage for glycopro-
teome analysis and the confidence of quantification results
of N-glycosites. In addition to trypsin, Glu-C and chymo-
trypsin were also applied to digest glycoproteins in this
study. Trypsin cleavages specifically the C-terminus of
basic residues (K and R), while Glu-C cuts the C-
terminus of acid residues (D and E) and chymotrypsin
cuts the C-terminus of hydrophobic residues (Y, W, F
and L). As the other two proteases have complementary
cleavage specificities to that of trypsin, it can be expectedthat many N-glycosites which cannot be identified by
trypsin digestion are possibly to be identified by other pro-
tease digestions. For the quantification of N-glycosites, it
is different with protein quantification in which the result
can be obtained by averaging all the quantification results
of different tryptic peptides from the parent protein.
Nevertheless, applying multiple protease digestion may
quantify different N-glycopeptides containing the same N-
glycosite. Thus the accuracy for the quantification results
of N-glycosites could be improved by averaging the ratios
of different N-glycopeptides containing the same N-glycosites.
Therefore, it can be expected that this integrated workflow
incorporated with multiple protease digestion and solid
phase based labeling can be applied to deeply inspect the
N-glycosite abundance differences of tissue glycoproteomes.
Evaluating the performance of the integrated workflow
Firstly, the integrated workflow was evaluated by quantita-
tive analysis of two identical samples, i.e. two aliquots of
the same protein extract from normal human liver tissue.
A total of 1,632 N-glycosites corresponding to 764 N-
glycoproteins were successfully quantified by the three di-
gestion strategies (Additional file 1: Table S1). Only one
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digestion. While for trypsin & Glu-C digestion, these two
proteases were added together into the samples for diges-
tion. This is because that Glu-C generated peptides are
too big to be identified by MS [19,21] and the in silico
sequence coverage for combined trypsin & Glu-C di-
gests was proved to achieve the greatest coverage [20].
The trypsin digestion leaded to quantification of only
1,037 N-glycosites, while the total number of quantified
N-glycosites reached 1,632 by using other two digestion
strategies (Figure 2A). The number increased by 57.4%
indicating the using of complementary proteases does
improve the N-glycoproteome coverage significantly.
Target/decoy search was performed in this study to con-
trol the confidence of peptide identifications. Among all
the quantified N-glycosites, only 5 N-glycosites were quan-
tified from decoy sequences. It was found the decoy identi-
fications were only found in the results from one digestion
strategy, while no decoy identification was observed for
overlapped quantified N-glycosites. Clearly the N-glycosites
quantified by more than one digestion strategy are more
confident simply because these sites were quantified by
multiple N-glycopeptides. Thus, the identification confi-
dence of the 47.1% of the total identified N-glycosites was
higher than that of others for they were observed in diges-
tion results from more than one digestion strategy.
Statistically, multiple measurements are essential to im-
prove the analysis accuracy. However, only one measure-
ment is done for conventional quantitative glycoproteomics
analysis as majority of N-glycosites are quantified by a sin-
gle glycopeptide. The main reason is that only one diges-
tion strategy, e.g. trypsin digestion, was commonly used.
While in this study some N-glycosites were quantified by
several glycopeptides thanks to the using of multiple pro-
teases. For example, the 13 amino acid sequence window
of N-glycosite N119 on ERAP2 is KDIEITNATIQSE. This
sites were quantified by three different glycopeptides, i.e.Figure 2 The venn diagram showing the overlap of the quantified N-
trypsin & Glu-C, chymotrypsin). (A) evaluation experiment, (B) differentia
the same protein extract from normal human liver tissue were light and he
For the differential analysis experiment, the samples of normal and HCC hu
respectively. One and three replicate 2D nanoLC-MS/MS runs of the labeled
experiment and differential analysis experiment, respectively.DIEITN*ATIQSEEDSR (N* indicates that asparagine was
detected with deamidation) with heavy/light ratio 0.85
by trypsin digestion, ITN*ATIQSEEDSR with heavy/light
ratio 1.03 by trypsin & Glu-C digestion, and IIIHSK-
DIEITN*ATIQSEEDSRY with heavy/light ratio 1.12 by
chymotrypsin digestion. Thus this N-glycosite was quanti-
fied to be heavy/light ratio of 1.00 by averaging above
three ratios. More importantly, RSD could be determined
for multiple measurements. For above case, the RSD was
determined to be 13.7%, indicating this site was reliably
quantified. The total quantified N-glycosites were classi-
fied into two groups: 1) the N-glycosites quantified from
more than one digestion strategy; 2) the N-glycosites
quantified from only one digestion strategy. For the first
group, RSD could be determined among the ratios ob-
tained from different digestion strategies. The RSD values
could be used to filter out the unreliable quantified results.
The distribution of the number of quantified N-glycosites
and the percentage of quantified ratio within the range of
0.5-2 across different RSD values are given in Additional
file 2: Figure S1. In proteomics, the quantified ratios in the
range of 0.5-2 are often considered as no significant change
[17,23-25]. In this evaluation experiment, two identical
samples were light and heavy labeled, the theoretical ratios
are 1:1 and the ratios for all quantified sites should be in
the range of 0.5-2. If the ratio beyond this range, it can be
considered as inaccurate quantification. It can be seen
from Additional file 2: Figure S1, only 1 of the 26 N-glyco-
sites (3.8%) were quantified with heavy/light ratio in the
range of 0.5-2 for N-glycosites with RSD > =50%. This
means that the quantified ratios with RSD > =50% are not
accurate. The percentage of quantified N-glycosites within
this ratio range increased to 100% when the RSD value fell
below 50%, and kept on 100% when the RSD value contin-
ued to decrease to 20%. But the number of quantified N-
glycosites filtered with RSD value decreased significantly
along with the decrease of the RSD value. So we adoptedglycosites by using three different digestion strategies (trypsin,
l analysis experiment. For the evaluation experiment, two aliquots of
avy labeled to evaluate the performance of the integrated workflow.
man liver tissues were labeled with light and heavy dimethyl labels,
sample were carried out for the evaluation
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tification and make relatively more peptides meeting the
criterion for research with no sacrifice of the confidence
of quantification. After filtering with RSD <50%, about
99.9% of the quantified N-glycosites were located in the
ratio range of 0.5-2 with only one exception for this group
(Figure 3A). While for the second group, among the 863
quantified N-glycosites, as many as 32 N-glycosites (about
4%) were located out of the ratio range of 0.5-2 (Figure 3A).
Obviously, as the sites were reproducibly quantified by
multiple glycopeptides, the quantitative results filtered by
RSD for the first group were more reliable. Though the
N-glycosites quantified from only one digestion strategy
were less reliable (group two), over 95% of the quantified
ratios located within the range of 0.5-2 indicated the
workflow has good performance in quantification. If the
confidence of quantification is defined as the percentage
of correctly quantified ratios (the ratios quantified in the
range of 0.5-2) among all quantified ratios, then the confi-
dence for above two classes of quantified ratios were 99.9%
and 95% respectively.Figure 3 The scatter diagram showing the log2 ratio distributions of
with RSD <50% (blue dot) and that from only one digestion strategy
experiment. The description for the two experiments was the same as in FDifferential analysis of the N-glycoproteome of normal
human liver tissues and human liver tissues with
hepatocellular carcinoma
This workflow was then applied to differential analysis of
the N-glycoproteome of HCC and normal human liver tis-
sues. Because of the undersampling problem of mass spec-
trometry (MS), the pooled labeled glycopeptides from
each digestion strategy were analyzed by 2D nanoLC-MS/
MS three times (three replicate runs) to achieve as much
information as possible for the sample. An average of
1,063 N-glycosites (RSD = 3.7%, n = 3) was quantified by
trypsin digestion, 1,046 N-glycosites (RSD = 1.6%, n = 3)
was quantified by trypsin & Glu-C digestion, and 301
N-glycosites (RSD = 8.1%, n = 3) was quantified by chymo-
trypsin digestion. The low RSD for the number of quanti-
fied N-glycosites among three replicates indicated the
good reproducibility of the workflow. Totally, 2,329 N-
glycosites corresponding 1,052 N-glycoproteins were
successfully quantified in the combined digestion results
from three digestion strategies, of which 754 N-glyco-
sites (32.4%) were additionally quantified by trypsin &N-glycosites quantified from more than one digestion strategy
(black dot). (A) evaluation experiment, (B) differential analysis
igure 2.
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Additional file 3: Table S2). First of all, the results were
filtered by the RSD criterion (RSD <50%) in three repli-
cates analyses of each digestion strategy to control the
quantification accuracy of technical replicates. Then the
filtered results of 2,101 N-glycosites were classified with
the method described above. 858 N-glycosites were ac-
curately quantified with RSD <50% for the ratios ob-
tained from more than one digestion strategy. 275 of
858 N-glycosites were located out of the ratio range of
0.5-2 (heavy/light ratio), which was considered to be of
significant expression change with more than 99% con-
fidence. 1,104 N-glycosites were only quantified from
only one digestion strategy, 428 of which with the ratio >2
or <0.5. These sites were significantly changed in abun-
dance with more than 95% confidence (Figure 3B).
Only the 858 N-glycosites with more than 99% confidence
were subjected to further investigation. The N-glycoproteins
containing the N-glycosites with or without significant
changes were all analyzed by GoMiner to obtain a com-
parative view of cellular component, biological process
and molecular function. For the 583 N-glycosites on 369 N-
glycoproteins determined without significant change betweenFigure 4 The bar graph showing the different subcategories of GO-an
change between the HCC and normal human liver tissues. (A) cellular
the classes with the difference in the percentages over 10% for the two tyHCC and normal human liver tissues, 328 proteins of
which were found to be gene ontology (GO)-annotated
proteins. And for the 275 N-glycosites on 215 N-glyco-
proteins determined with significant change, 190 pro-
teins of which were with GO annotation. Comparing
the N-glycoproteins with significant change and that with-
out significant change, the percentage of GO-annotated
proteins related with the intracellular organelles in the
process of glycoprotein synthesis such as golgi apparatus
and endoplasmic reticulum was decreased by more than
10% (Figure 4A). Meanwhile, for the N-glycoproteins with
subcellular annotation of “plasma membrane” and “extra-
cellular region”, both the proportions were increased by
more than 10% in the part of N-glycoproteins with signifi-
cant change. It can be inferred that the enhanced tranport
of N-glycoproteins from the intracellular organelles to
extracellular matrix may play a vital role in the develop-
ment of HCC. The featured biological processes in-
volved with membrane proteins and secreted proteins,
such as “multicellular organismal process”, “developmen-
tal process”, “signaling”, “cellular component organization
or biogenesis”, “immune system process”, “biological
adhension” and “response to external stimulus”, werenotated proteins for N-glycoproteins with and without significant
components, (B) biological processes and molecular functions. Only
pes of N-glycoproteins were given.
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N-glycoproteins part versus the no-change part. Additionally,
the molecular functions characteristic for N-glycoproteins,
e.g. “catalytic activity”, “receptor activity”, “enzyme regulator
activity” and “structural molecule activity”, were also
represented differently by more than 10% between the
N-glycoproteins part with and without significant change
(Figure 4B). Therefore, the differential expressed N-
glycoproteins related with these biological processes
and molecular functions mentioned above may con-
tribute greatly to the progression of HCC, but further
investigations were still needed.
Discussion
Glycoproteins with different linkage of various glycans
to Asparagine get involved in multiple critical biological
processes, such as cell adhesion, cell migration, signal
transduction, receptor activation and so on [26]. Dysreg-
ulation of glycoprotein, either on the glycan part or the
polypeptide part, is associated with many types of dis-
eases, e.g. cancer, diabetes mellitus, congenital disorder,
arthritis, inflammation and so on [26-28]. Although the
high-throughput identification of N-glycosites has been
extensively carried out on varieties of biological samples,
such as mouse tissues [29], human serum/plasma [6,30],
seven major model organisms [31], the large scale quanti-
tative analysis of N-glycosites were still lacked and ur-
gently needed. So we designed this integrated workflow
incorporating multiple protease digestion and solid phase
based labeling method to investigate the differential ex-
pression in the N-glycoproteome of HCC and normal hu-
man liver tissues.
Nonenzymatic deamidation of glutamine and aspara-
gine occurs spontaneously on proteins and peptides both
in vivo and in vitro. For large-scale proteomics analysis,
the determination of N-glycosites generally depends on
the detection of the deamidation of asparagine in the
peptides containing the consensus motif N-X-S/T (X can
be any amino acid except proline). Because the nonenzy-
matic deamidation can also occur on the asparagine in
the consensus sequence which is not actually occupied
by a glycan, this may cause false positive identification of
N-glycosites [32]. Hao et al. ascertained that nonenzy-
matic asparagines deamidation occurred to some extent
on 4-9% of the peptides obtained by an electrostatic
repulsion-hydrophilic interaction chromatography (ERLIC) –
reverse phase (RP) chromatography, resulting in the
false positive identifications of many N-glycosites [33].
Zielinska et al. [29] have used H2
18O to differentiate na-
tive deamidation sites from those occurring during sam-
ple preparation, but their approach cannot distinguish
the nonenzymatic deamidation that occurs in the con-
sensus sequence during the PNGase F treatment from
the real N-glycosites. Compared with above mentionedmethods, our workflow was based on solid phase. Se-
quences with nonenzymatic deamidation that occurs
during sample preparation can be cleaned away from
the surface of hydrazide resins by rigorous and repeated
washings. The only factor in our workflow which may
cause false positive identifications was the incubation
with PNGase F in the 37°C overnight. To estimate the
false positive identifications in our workflow, a negative
control with the same experimental procedures but with
the omission of PNGase F addition was carried out. Less
than 1% of the total quantified N-glycosites in the con-
sensus sequences were also quantified in the negative
control (data not shown). Consequently, the false posi-
tive identifications caused by nonenzymatic deamida-
tion can be neglected in our workflow.
For large scale proteomic analysis, it would cost sev-
eral days of precious MS times to analyze a couple of
samples [15,34]. It is impractical to analyze large number
of samples via large scale proteomics approaches. Ac-
cording to the process flow for the development of novel
protein biomarker candidates described by Rifai et al.
[35], a simplified, binary comparison between diseased
and normal tissues was usually performed by proteomics
methods based on MS for the discovery of biomarker
candidates. So in practice, different samples were pooled
together to reduce the biological variation [29,36-38].
For further analysis, the molecules screened out by large
scale proteomics should be individually validated in each
case among a large cohort of samples which may involve
the environmental, genetic, biological and stochastic
variation [39,40]. Our integrated workflow was aimed to
provide lists of potential biomarker candidates by differ-
entially analyzing the N-glycoproteome between HCC
and normal human liver tissues in a high-throughput
manner.
Among the total of 455 N-glycoproteins which was deter-
mined with significant change between HCC and normal
human liver tissues in our experiment, 116 N-glycosylated
molecules are found to be related with various types of
human disease in the biomarker filter analysis by Ingenu-
ity Pathway Analysis (IPA), such as cancer, cardiovascular
disease, immunological disease and so on. Furthermore,
some of the 90 N-glycosylated molecules involved in the
human liver diseases are previously reported to be associ-
ated with liver cancer (Additional file 4: Table S3). For
example, decorin (DCN), a secreted small leucine-rich
proteoglycan, has three N-glycosites annotated by Swiss-
Prot (N211, N262, N303), two of which were determined
with decreased level in HCC versus normal liver tissues
(N262 0.65, N303 0.47). Our result was consistent with
the findings of Baghy et al., in which the idea that decorin
acts as a secreted tumor repressor during hepatocarcino-
genesis by hindering the action of another receptor tyrosine
kinase, such as the PDGFRα, was supported and DCN was
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liver cancer [41]. GPNMB, with N-glycosites of N128
quantified with increased level in HCC in our study, was
also demonstrated with significantly enhanced expression
level in HCC compared with adjacent normal liver tissues
by using histochemical method in the study of Tian et al.
[42]. Subramaniam et al. have viewed specific suppression
of IGFBP3 expression in primary human HCC tissues
compared to adjacent histologically normal tissues [43],
while the significant down-regulation of IGFBP3 (N116
0.4) were also observed in our experiment. Besides, many
N-glycosyalted molecules which may also be involved in
other types of cancer were also detected in our results, e.g.
elevated ALCAM shedding in colorectal cancer was corre-
lated with poor patient outcome [44], BMPR2 participated
in the regulation of endoglin-mediated suppression of
prostate cancer invasion [45], CD36 was demonstrated to
be an important index for predicting the occurrence and
development of radiation pneumonitis and evaluating the
curative effect [46], etc.Conclusions
Quantitative proteome analysis is a valuable tool to screen
the disease-specific biomarkers. In this work, an integrated
glycoproteomics workflow was applied to differential ana-
lysis of N-glycoproteome between HCC and normal hu-
man liver tissues. Multiple protease digestion was also
integrated with the solid phase based labeling to increase
the coverage of human liver N-glycoproteome analysis
and the confidence of the quantified N-glycopeptides. A
total of 2,329 N-glycosites matched with the motif N-X-S/T
(X can be any amino acid except proline) on 1,052 N-
glycoproteins were successfully quantified. Consequently,
our integrated workflow will also perform effectively when
targeting general population screening of differential N-
glycoproteins in HCCs, and provides a valuable public
dataset for further verification and validation of potential
biomarker candidates of HCC.Methods
Protein extraction
The HCC and normal human liver tissues were provided
by Second Affiliated Hospital of Dalian Medical University
(Dalian, China). The normal human liver tissues were the
noncancerous liver tissues ≥ 2 cm outside the hepatic can-
cer nodules removed by surgical operation from patients.
The noncancerous liver tissue has been verified by histo-
pathological examination which excluded the presence of
invading or microscopic metastatic cancer cells. The HCC
tissues were obtained from the HCC patients of advanced
stage by surgical operation. The utilization of human tis-
sues was complied with guidelines of Ethics Committee of
the Hospital.The isolated human liver tissue was cut into pieces at
first and washed several times with PBS buffer to remove
the remaining blood. For large scale proteomic analysis,
the noncancerous liver tissues from five patients with
hepatic cancer were pooled together to reduce the bio-
logical variation [29,36-38], and so were the HCC tis-
sues. Then the liver tissue was placed in an ice-cold
homogenization buffer I (10 mM HEPES, 1.5 mM
MgCl2, 5 mM KCl, 0.1 mM EDTA, 2% protease inhibi-
tor cocktail (pH = 7.4)), followed by homogenization
using an IKA Ultra Turbax blender. After that, the tissue
was transferred into a Potter-Elvejhem homogenizer with
a Teflon piston and homogenized for a second time on
the ice. The supernatant was collected after centrifugation
of the homogenates at 1,000 g for 5 min to pellet the nu-
clei and debris. Then 5 volumes of buffer II (0.1 M Tris–
HCl, 4% SDS, 1% Triton, pH = 7.4) was added to the sam-
ple for sonication using an ultrasonic cell disrupter (3 s
with 3 s intervals for 180 times at 400 W) and centrifuged
at 20,000 g for 15 min. The supernatant was collected
and the concentration of proteins was measured by
BCA assay.
Oxidation of glycan and enrichment of N-glycoproteins
Three batches of 2 mg human liver extract were pre-
treated in parallel. Firstly, the samples were desalted
with Zeba spin desalting column (Thermo Scientific, USA)
after incubation in boiling water for 10 min. Then the
desalted solutions were resuspended with oxidation buffer
(150 mM NaCl + 100 mM NaAc + 2% SDS + 2% Triton,
pH 5.5). Sodium periodate was added into the solutions to
oxidize the glycan in the dark at room temperature for
1 h. Finally, the oxidized samples were added into the pre-
washed hydrazide resins (Bio-Rad, USA) after quenching
the oxidation reaction with sodium thiosulfate. The coup-
ling reaction was performed with gentle shaking at room
temperature overnight.
Digestion of the captured N-glycoproteins on hydrazide
resins with multiple proteases
After the removal of supernatant, the resins with cap-
tured N-glycoproteins were diluted with 50 mM Tris +
1% SDS + 1% Triton (pH = 8). The glycoproteins on the
resins were reduced with 20 mM dithiothreitol at 37°C
for 2 h and carboxyamidomethylated with 40 mM iodoa-
cetamide at room temperature for 40 min in the dark.
Then 100 mM NH4HCO3, 80% ACN and 100 mM
NH4HCO3 were sequentially added to wash the resins
to remove non-specifically bound proteins. Trypsin,
trypsin & Glu-C, and chymotrypsin were chose as pro-
teases to digest the three batches of captured glycopro-
teins on the resins respectively. For trypsin & Glu-C
digestion, the two proteases were added into the sample
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were all the same but different with the quantity of prote-
ases added.
After the last wash of 100 mM NH4HCO3, each prote-
ase was added to digest the captured glycoproteins. The
digest conditions of each protease were described as fol-
lows: Trypsin (Sigma-Aldrich, USA) was added with a
weight ratio of trypsin to protein at 1/25 and incubated at
37°C overnight; Trypsin & Glu-C were added with a weight
ratio of trypsin to protein at 1/25 and Glu-C (Roche,
Germany) to protein at 1/20 and incubated at 37°C over-
night; Chymotrypsin (Sigma-Aldrich, USA) was added with
a weight ratio of chymotrypsin to protein at 1/10 and incu-
bated at 37°C overnight.
Dimethyl labeling the captured N-glycopeptides on the
hydrazide resin and releasing N-glycopeptides from
hydrazide resins
After incubation with the selected protease overnight,
1.5 M NaCl, 80% ACN and 100 mM NH4HCO3 were
added sequentially to wash away the digested peptides
from resins. As described in our previous work [12],
400 μL 100 mM TEAB was added to the hydrazide resins,
followed by the addition of 32 μL 4% CH2O/CD2O to the
sample to be light or heavy labeled respectively and the
additional addition of 32 μL 0.6 M NaBH3CN to both
samples. The dimethyl labeling reaction was carried
out at room temperature for 2 h with gentle shaking.
After rinsing the hydrazide resins twice with deionized
water to remove the remaining dimethyl labeling re-
agents, the N-glycopeptides were released by adding
1,000 unit PNGase F (New England Biolabs, USA) in
10 mM NH4HCO3 to the resins and incubating at 37°C
overnight with gentle shaking. The released deglycosyl-
ated peptides were carefully collected by gentle centri-
fugation.
Mass spectrometry data acquisition
The enriched N-glycopeptides were analyzed by 2D
nanoLC-MS/MS system [17] on LTQ-Orbitrap Velos
(Thermo, San Jose, CA, USA) and one tenth of the labeled
N-glycopeptides were analyzed each time. The LTQ-
Orbitrap Velos system was equipped with an Accela 600
HPLC (Thermo, San Jose, CA, USA) involving a 7 cm
phosphate monolithic trap column and a 12 cm C18 capil-
lary analysis column with spray emitter. The SCX column
was prepared by the same method as described by Wang
et al. [47] and separation column was packed with C18
AQ beads (3 μm, 120 Å). Formic acid water solution
(Buffer A) and pure acetonitrile (ACN) with 0.1% formic
acid (Buffer B) were used for the generation of linear gra-
dient for RPLC separation. The peptide sample was firstloaded onto the monolithic trap, then a series stepwise
elution with salt concentrations of 100, 200, 300, 400, 500
and 1,000 mM NH4Ac was used to gradually elute pep-
tides from the phosphate monolithic column onto the
C18 analytical column. After each salt elution, binary sep-
aration gradient from 5% to 35% in 120 min with a flow
rate of ∼ 300 nL/min was applied to separate peptides
prior to MS detection.
A spray voltage of 2.2 kV was applied between the
spray tip and the MS interface. The temperature of the
ion transfer capillary was set as 250°C. The mass spec-
trometer was set that one full MS scan was followed by
20 MS/MS scans on the 20 most intense ions by colli-
sion induced dissociation (CID). 300 was set as the mini-
mum signal threshold for MS/MS scan. The normalized
collision energy was set at 35.0%, and the activation time
was 10 ms. The mass resolution was set at 60 000 for
full MS. The dynamic exclusion was set as follows: repeat
count, 1; duration, 30 s; exclusion list size, 500; exclusion
duration, 90 s. The scan range was set from m/z 400 to
2,000. System control and data collection were carried out
by Xcalibur software version 2.1.Protein identification and quantification
All the RAW files collected by Xcalibur 2.1 were searched
by MaxQuant version 1.2.2.5 against a composite database
including original and reversed human protein database
of International Protein Index (IPI human v3.80 fasta,
including 86,719 entries, ftp://ftp.ebi.ac.uk/pub/databases/
IPI). The parameters were set as follows: proteases, trypsin,
2 missed cleavages (trypsin & Glu-C, 4 missed cleavages or
chymotrypsin, 4 missed cleavages); static modification,
Cysteine Carboxamidomethylation; variable modification,
oxidation of methionine and deamidation of glutamine/
asparagine; mass tolerance, 20 ppm for parent ions and
0.5 Da for fragment ions. For the quantitative analysis of the
results, peptide N termini and the side chain of lysine resi-
dues were set with light (+28.0313 Da) and heavy dimethy-
lation labels (+32.0564 Da). The false detection rate (FDR)
was determined by equation of FDR = [2 × FP / (FP +TP)] ×
100%, where TP (true positive) is the number of peptides
that were identified based on sequences in the forward data-
base component and FP (false positive) is the number
of peptides that were identified based on sequences in the
reverse database component. The FDR values for peptide
identifications were controlled less than 1%. GoMiner,
the software which can make the biological interpret-
ation in the context of the Gene Ontology [48], was
applied to classify the cellular component, biological
process and molecular function of the quantified
N-glycoproteins between HCC and normal human
liver tissues with the newly updated database
(version_go_201202).
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